Garassino Highlights ASCO NSCLC Findings and Looks to the Future

July 3, 2018 – In the wake of recent data presented at the 2018 ASCO Annual Meeting, the landscape of non–small cell lung cancer (NSCLC) continues to rapidly shift. Immunotherapy has consistently shown promise, but the future of treatment for many patients may be with combination chemoimmunotherapy, said Marina Chiara Garassino, MD. During the meeting, Garassino presented updated data from the phase II ATLANTIC study, which investigated the PD-L1 inhibitor … (leggi tutto)